Guest: S. Michelle Shiller, DO, AP/CP, MGP

Guest: John V. Heymach, MD, PhD

Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.

All trademarks are the property of their respective owners.
©2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
December, 2021. VV-MEDMAT-56973